Type: Next-generation Pan-COVID-19 vaccine candidate designed to protect against current and potentially future variants of concern
Status: INOVIO said May 12 that INO-4802 induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant) in preclinical models. These results, posted May 11 in a preprint study in bioRxiv, showed what INOVIO said was the potential of the Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a boost for individuals previously immunized with various Wuhan-matched vaccines.
INOVIO plans to conduct Phase I/II clinical trials of INO-4802 this year.
COVID-19: 300 Candidates and Counting
To navigate through the >300 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: